Skip Navigation


European Heart Journal Advance Access originally published online on April 21, 2009
European Heart Journal 2009 30(11):1307-1309; doi:10.1093/eurheartj/ehp169
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/11/1307    most recent
ehp169v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pitt, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pitt, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Angiotensin-converting enzyme inhibitors in patients with vascular disease

Bertram Pitt*

University of Michigan School of Medicine, 1500 E. Medical Center Drive, Cardiovascular Center, Ann Arbor, MI 48109, USA

* Corresponding author. Tel: +1 734 9365260, Fax: +1 734 936;5256, Email: bpitt@umich.edu

This editorial refers to ‘The consistency of the treatment effect of an ACE inhibitor-based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials’{dagger}, by J.J. Brugts et al., on page 1385

The first 10% of the full text of this article appears below.

Angiotensin-converting enzyme inhibitors (ACEIs) have a beneficial effect on oxidative stress, endothelial function, vascular remodelling, and the progression of atherosclerosis in animal experiments independent of their effect on reducing blood pressure. ACEIs have also been shown to decrease cardiovascular mortality and morbidity in patients with vascular disease.1,2 While these results have been adopted into guidelines, there have been doubts as to whether or not these benefits were due to a reduction in blood pressure and therefore possibly any anti-hypertensive strategy might be equally effective or whether they have an effect independent of blood pressure lowering. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials
Jasper J. Brugts, Toshiharu Ninomiya, Eric Boersma, Willem J. Remme, Michel Bertrand, Roberto Ferrari, Kim Fox, Stephen MacMahon, John Chalmers, and Maarten L. Simoons
EHJ 2009 30: 1385-1394. [Abstract] [Full Text]